Haemonetics reports Q2 growth, raises FY2027 revenue guidance but trims margin outlook
Haemonetics announced 10% organic revenue growth in Q2 and lifted its FY2027 organic revenue guidance to 6%‑9% from 4%‑7%. Adjusted earnings per share rose 6% to $1.35 for the quarter. The company warned that higher personnel, production and freight costs will curb operating‑margin expansion, lowering its FY2027 margin‑expansion target to 0‑50 basis points. Management highlighted a multiyear growth opportunity with CSL and new product launches, while noting that margin benefits from the CSL deal are expected in FY2028.
Why it matters
The higher revenue outlook suggests stronger top‑line momentum, but the reduced margin‑expansion guidance signals near‑term pressure on profitability (the company said margin expansion will be limited to 0‑50 bps in FY2027). Investors will need to weigh the upside from the CSL partnership against the transitory cost headwinds.
Key facts
- 1Q2 organic revenue grew 10%. tipranks.com
- 2Adjusted earnings per diluted share were $1.35 for the quarter. tipranks.com
- 3First‑half operating cash flow increased 40% to $180 million. tipranks.com
- 4Second‑quarter adjusted gross margin improved 140 basis points to 61.9%. tipranks.com
- 5FY2027 organic revenue growth guidance was raised to 6%‑9%. tipranks.com
- 6FY2027 adjusted operating‑margin expansion target was lowered to 0‑50 basis points. finance.yahoo.com
Summary written by AlphAI AI Desk from 3 of 3 sources. Not investment advice. Figures are as stated by the linked sources.